Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an update.
Hemogenyx Pharmaceuticals has secured £250,000 to continue its Phase 1 clinical trials for its Chimeric Antigen Receptor T-cell therapy aimed at treating relapsed/refractory acute myeloid leukemia in adults. This funding, raised through an allotment to CEO Vladislav Sandler, reflects investor confidence in the company’s progress and potential, as evidenced by the premium issue price of the shares.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company based in London, with subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing several distinct product candidates and platform technologies.
Average Trading Volume: 37,697
Technical Sentiment Signal: Sell
Current Market Cap: £7.71M
For an in-depth examination of HEMO stock, go to TipRanks’ Overview page.